Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

24432 ARTÍCULOS , VIENDO DEL 151 AL 165

Can the integration of blood-based biomarkers into Alzheimer's disease diagnosis revolutionize the field?

Gaetani L, Nardi G, Parnetti L.

Expert Rev Neurother. 2026 Sep;26(9):839-852. doi: 10.1080/14737175.2026.2700246. Epub 2026 Jul 7.

Immunotherapy with a short-lived anti-PD-L1 antibody in Alzheimer's disease: a phase 1b, randomized, double-blind trial

Croese T, Mummery CJ, Bregman N, Bracha D, Baruch K, Kertser A, Raveh S, Shochat E, Schwartz M.

Nat Med. 2026 Sep;32(9):3458-3465. doi: 10.1038/s41591-026-04547-8. Epub 2026 Jul 15.

Do sigma-1 receptor agonists offer therapeutic promise for Alzheimer's disease?

Panza F, Dibello V, Daniele A, Lozupone M.

Expert Opin Pharmacother. 2026 Aug;27(12):1243-1250. doi: 10.1080/14656566.2026.2706070. Epub 2026 Jul 20.

Acitretin-inspired medicinal chemistry for Alzheimer's disease: A biomarker-gated central nervous system (CNS) discovery framework

Qin TG, Han Y.

Drug Discov Ther. 2026 Sep 21;20(4):349-353. doi: 10.5582/ddt.2026.01054. Epub 2026 Aug 18.

Emerging diagnostic biomarkers and therapeutic targets in Alzheimer's disease

Dineshbhai TK, Rafaliya D, Singh A, Maheshwari S, Lalan M, Chakraborthy GS.

Inflammopharmacology. 2026 Sep;34(9):6003-6034. doi: 10.1007/s10787-026-02341-z. Epub 2026 Aug 22.

EOAD-Signature Atrophy Predicts Dementia in Early-Onset MCI due to Alzheimer Disease: An MRI-Based Prognostic Biomarker

Paranhos T, Katsumi Y, Brickhouse MJ, Eloyan A, Eckbo R, Zaitsev A, Du A, La Joie R, Thangarajah M, Taurone A, Vemuri P, Jack CR; as the LEADS Consortium; Hammers DB, Aisen PS, Beckett LA, Koeppe R, Kukull WA, Toga AW, Atri A, Clark DG, Day GS, Duara R, Graff-Radford NR, Grant IM, Honig LS, Johnson E, Jones DT, Masdeu JC, Mendez MF, Musiek ES, Onyike CU, Riddle M, Rogalski E, Salloway S, Sha SJ, Turner RS, Wingo T, Wolk DA, Womack KB, Carrillo MC, Rabinovici GD, Apostolova LG, Dickerson BC, Eldaief MC, Touroutoglou A.

Neurology. 2026 Oct 13;107(7):e218519. doi: 10.1212/WNL.0000000000218519. Epub 2026 Aug 26.

Rethinking tau-targeted therapy in Alzheimer's disease: Toward a dual biomarker strategy

Teunissen CE, Pini L, Imbimbo BP.

Alzheimers Dement. 2026 Sep;22(9):e71867. doi: 10.1002/alz.71867.

Overview in Electrochemical and Electrical Biosensors for Determining Blood Protein Biomarkers of Alzheimer's Disease

Gao F, Liu L, Li J, Chen S, Yi X.

Biosensors (Basel). 2026 Aug 6;16(8):426. doi: 10.3390/bios16080426.

Neuropsychiatric symptoms as early clinical indicators and functional biomarkers of cognitive decline in mild cognitive impairment and early Alzheimer's disease

de Levante Raphael D.

J Alzheimers Dis. 2026 Sep;113(1):5-15. doi: 10.1177/13872877261469114. Epub 2026 Jul 27.

Head-to-head comparison of plasma biomarker assays across platforms for amyloid pathology in a multicenter cohort

Lv X, Shen K, Zhao Q, Peng G, Liu H, Gao F, Pan X, Chen W, Lu P, Zhang H, Zhang S, Xing M, Chen Q, Wang Y, Cheng Z, Wang Y, Zeng S, Xie F, Pan Y, Shen Y, Chen X, Shi J.

Sci Bull (Beijing). 2026 Sep 15;71(17):4506-4515. doi: 10.1016/j.scib.2026.08.018. Epub 2026 Aug 5.

Progress in Optical Methods for the Detection of Two Core Blood Biomarkers of Alzheimer's Disease: Amyloid-Beta and Tau Proteins

Xia N, Gao F, Zheng C.

Biosensors (Basel). 2026 Aug 6;16(8):427. doi: 10.3390/bios16080427.

Chronic kidney disease and cognitive decline: choroid plexus remodeling, glymphatic dysfunction, and alzheimer biomarker interpretation

Corrêa LMA, Oliveira da Silva R, Brandão LKV, Delmiro Silva YR, da Silva ÉVB, Tretow J, Gomes EDC, Fernandes CCS, Moreira GNCM, Zanella J.

Neurol Sci. 2026 Sep 11;47(10):774. doi: 10.1007/s10072-026-09362-0.

Olfactory-Cleft Biopsy in Alzheimer's Disease: An Emerging Neuroimmune Window into Preclinical Pathobiology

Chmiel J, Kładna A.

Int J Mol Sci. 2026 Sep 10;27(18):8043. doi: 10.3390/ijms27188043.

Classification accuracies of plasma ptau217 vs. ptau217/Aβ1-42 for brain Aβ pathology in cognitively normal older adults

Olvera-Rojas M, Solis-Urra P, Fernandez-Gamez B, Coca-Pulido A, Triviño-Ibáñez EM, Zeng X, Oberlin LE, Gispert JD, Erickson KI, Gómez-Río M, Karikari TK, Ortega FB, Esteban-Cornejo I.

Geroscience. 2026 Aug;48(4):5695-5708. doi: 10.1007/s11357-025-01967-1. Epub 2025 Nov 6.

Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial

Fleisher AS, Munsie L, Mancini M, Cheng YJ, Guo J, Nuthall H, Otero DS, Kotari V, Kielbasa W, Hutton M, Brys M, Mergott DJ, Mintun M, Hansson O.

JAMA. 2026 Sep 22;336(12):1017-1028. doi: 10.1001/jama.2026.12768.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias